You are here

Celladon Receives Patent for Heart Failure Drug

Mydicar is a genetically targeted enzyme replacement therapy intended to restore levels of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a), a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage heart failure, resulting in deficient heart function. With Mydicar, the SERCA2a gene is delivered using recombinant adeno-associated virus as the vector.

Mydicar is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. The drug is synergistic and additive across current heart failure treatments, such as angiontensin-converting enzyme (ACE) inhibitors, beta-blockers, spironolactone/diuretics, and biventricular pacing devices.

Read the news release, available here.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients